Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.79 |
| ▸ | KDR | P35968 | 12/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.64 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CDK2 | P24941 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.53 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 6/20 | 0.45 |
| ▸ | LCK | P06239 | 5/20 | 0.44 |
| ▸ | YES1 | P07947 | 5/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | FYN | P06241 | 4/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.44 |
| ▸ | NEK2 | P51955 | 3/20 | 0.44 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412097 | 0.94 | MET (0.70) | METKDRFGFR1PTK2BMEN1 | |
| SCHEMBL5405519 | 0.89 | MET (0.61) | METKDRFGFR1PTK2BMEN1 | |
| SCHEMBL2046935 | 0.88 | MET (1.00) | METKDRFGFR1PTK2BMEN1 | |
| SCHEMBL31016301 | 0.88 | MET (1.00) | METKDRFGFR1PTK2BMEN1 | |
| SCHEMBL29394654 | 0.88 | MET (1.00) | METKDRFGFR1PTK2BMEN1 | |
| SCHEMBL2045771 | 0.88 | MET (1.00) | METKDRFGFR1PTK2BMEN1 | |
| SCHEMBL5410105 | 0.86 | MET (0.61) | METKDRFGFR1PTK2BMEN1 | |
| SCHEMBL5396486 | 0.85 | KDR (0.61) | METKDRFGFR1PTK2BPDGFRB | |
| SCHEMBL5410964 | 0.84 | KDR (0.60) | METKDRFGFR1PTK2BPDGFRB | |
| SCHEMBL5396485 | 0.83 | KDR (0.58) | METKDRFGFR1PTK2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | MET 2590/4885KDR 1657/4885FGFR1 1118/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | MET 2434/4885KDR 1541/4885FGFR1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.